From the blog

Decision Making Tools for Mesothelioma

Mesothelioma, a cancer mainly caused by asbestos exposure, is very rare and aggressive. There are many challenges that doctors face when diagnosing, treating, and managing this cancer. Advances in medical technology and data analytics are helping doctors make crucial decisions for patients struggling with the hard to treat and deadly[…]

Read More »

MARS 2 Trial for Mesothelioma

Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]

Read More »

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)

Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]

Read More »

Changing Gut Bacteria Could Improve Effectiveness of Certain Treatments for Mesothelioma

A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the body including the lungs, abdomen, heart, and testicles. This has led experts to believe that in future cases of mesothelioma,[…]

Read More »

New Testing for Asbestos in Talc Based Products

In 2023, Congress passed a new law requiring that the U.S. Food and Drug Administration release new industry standards for asbestos testing in products. The agency will require all talc-containing products to be tested for asbestos. This new proposal follows years of lawsuits against Johnson & Johnson and other companies[…]

Read More »

New Blood Test for Mesothelioma

Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for targeted therapies. The test works by finding complex DNA patterns that are common in mesothelioma cells. The new approach is[…]

Read More »

Keytruda and Chemotherapy Approved for the Treatment of Mesothelioma

A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically for Keytruda alongside pemetrexed and platinum chemotherapy. The approval follows the promising results in phases 2 and 3 of the[…]

Read More »

Immune Checkpoint Inhibitors for the Treatment of Mesothelioma

Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new study from Australia has raised questions about the effectiveness and safety of this novel treatment. In order to best care[…]

Read More »

Study of ISM6331 in Participants With Advanced/​Metastatic Malignant Mesothelioma or Other Solid Tumors

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).

Read More »

Skip to content